These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23687087)

  • 21. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
    Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
    BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
    Van Meter ME; Díaz-Flores E; Archard JA; Passegué E; Irish JM; Kotecha N; Nolan GP; Shannon K; Braun BS
    Blood; 2007 May; 109(9):3945-52. PubMed ID: 17192389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
    Carr RM; Vorobyev D; Lasho T; Marks DL; Tolosa EJ; Vedder A; Almada LL; Yurcheko A; Padioleau I; Alver B; Coltro G; Binder M; Safgren SL; Horn I; You X; Solary E; Balasis ME; Berger K; Hiebert J; Witzig T; Buradkar A; Graf T; Valent P; Mangaonkar AA; Robertson KD; Howard MT; Kaufmann SH; Pin C; Fernandez-Zapico ME; Geissler K; Droin N; Padron E; Zhang J; Nikolaev S; Patnaik MM
    Nat Commun; 2021 May; 12(1):2901. PubMed ID: 34006870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulating Notch counteracts Kras
    Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
    Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
    Parikh C; Subrahmanyam R; Ren R
    Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEK1 is required for the development of NRAS-driven leukemia.
    Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
    Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.
    Lee BH; Tothova Z; Levine RL; Anderson K; Buza-Vidas N; Cullen DE; McDowell EP; Adelsperger J; Fröhling S; Huntly BJ; Beran M; Jacobsen SE; Gilliland DG
    Cancer Cell; 2007 Oct; 12(4):367-80. PubMed ID: 17936561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.
    Caraffini V; Geiger O; Rosenberger A; Hatzl S; Perfler B; Berg JL; Lim C; Strobl H; Kashofer K; Schauer S; Beham-Schmid C; Hoefler G; Geissler K; Quehenberger F; Kolch W; Athineos D; Blyth K; Wölfler A; Sill H; Zebisch A
    Haematologica; 2020; 105(2):375-386. PubMed ID: 31097632
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-leukemic effects of simvastatin on NRAS
    Jang J; Lee J; Jang JH; Jung CW; Park S
    Mol Biol Rep; 2019 Dec; 46(6):5859-5866. PubMed ID: 31452046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.
    Wang T; Li C; Xia C; Dong Y; Yang D; Geng Y; Cai J; Zhang J; Zhang X; Wang J
    Am J Transl Res; 2015; 7(10):1963-73. PubMed ID: 26692939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
    J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
    Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
    Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Carratt SA; Braun TP; Coblentz C; Schonrock Z; Callahan R; Curtiss BM; Maloney L; Foley AC; Maxson JE
    Leukemia; 2021 Dec; 35(12):3594-3599. PubMed ID: 34002029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice.
    Harada N; Hasegawa A; Hirano I; Yamamoto M; Shimizu R
    Cancer Sci; 2019 Apr; 110(4):1183-1193. PubMed ID: 30710465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
    Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
    Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adaptive endoplasmic reticulum stress signalling via IRE1α-XBP1 preserves self-renewal of haematopoietic and pre-leukaemic stem cells.
    Liu L; Zhao M; Jin X; Ney G; Yang KB; Peng F; Cao J; Iwawaki T; Del Valle J; Chen X; Li Q
    Nat Cell Biol; 2019 Mar; 21(3):328-337. PubMed ID: 30778220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.